1242137-16-1

Basic information

• Product Name: N-desMethyl EnzalutaMide
• Synonyms: N-desMethyl EnzalutaMide;4-[3-[4-Cyano-3-(trifluoroMethyl)phenyl]-5,5-diMethyl-4-oxo-2-thioxo-1-iMidazolidinyl]-2-fluorobenzaMide;Enzalutamide impurity B
• CAS NO: 1242137-16-1
• Molecular Formula: C₂₀H₁₄F₄N₄O₂S
• Molecular Weight: 450.4093728
• Product Categories: Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 1242137-16-1.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Amber Vial, Refrigerator
• Solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Very Slightly, Heated)
• Stability: Light Sensitive
• CAS DataBase Reference: N-desMethyl EnzalutaMide(CAS DataBase Reference)
• NIST Chemistry Reference: N-desMethyl EnzalutaMide(1242137-16-1)
• EPA Substance Registry System: N-desMethyl EnzalutaMide(1242137-16-1)

Safety Data

• Hazardous Substances Data: 1242137-16-1(Hazardous Substances Data)

Usage

Uses

Used in Hormone Receptor-Related Disorders:
N-desmethyl Enzalutamide is used as a therapeutic agent for disorders involving androgen, estrogen, and progesterone receptors. It targets these hormone receptors, potentially leading to the regulation or inhibition of hormone-related processes, which can be beneficial in treating various conditions associated with hormonal imbalances or hormone receptor dysfunction.
The compound's ability to interact with multiple hormone receptors makes it a versatile and promising candidate for the treatment of a wide range of disorders, including but not limited to, certain types of cancer, endocrine disorders, and reproductive system conditions. Further research and clinical trials are necessary to fully understand the potential applications and limitations of N-desmethyl Enzalutamide in the treatment of these disorders.

Upstream product

• 1242137-21-8 methyl 2-(4-carbamoyl-3-fluorophenylamino)-2-methylpropanoate 
• 143782-23-4 4-isothiocyanato 2-(trifluoromethyl)benzonitrile 
• 112704-79-7 2-fluoro-4-bromobenzoic acid 
• 179232-29-2 methyl 4-bromo-2-fluorobenzoate 
• 1802242-43-8 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluorobenzoic acid methyl ester 

Downstream Products

• 1242137-17-2 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-2,4-dioxoimidazolidin-1-yl)-2-fluorobenzamide 

Relevant articles and documents

ENZALUTAMIDE DERIVATIVES FOR THE TREATMENT OF PROSTATE AND BREAST CANCER

The invention provides a compound of formula (I) or (I') or a pharmaceutically acceptable salt thereof. Also provided are pharmaceutical compositions comprising the compounds, processes for preparing the compounds and medical uses of the compounds.

An improved and practical route for the synthesis of enzalutamide and potential impurities study

An improved and practical synthesis of enzalutamide was accomplished in five steps. Starting from 4-bromo-2-fluoro-benzonic acid, a methyl esterification, Ullmann ligation, methyl esterification, ring closing reaction and final methyl amidation provided the target in 35% total yield with 99.8% purity. Five identified impurities were also synthesized. This efficient and economical procedure avoids the use of highly toxic reagents and multiple recrystallization operations, which is suitable for further industrialization.

SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS

Compositions, such as pharmaceutical compositions, comprising specific diarylhydantoin and diarylthiohydantoin compounds, or salts or solvates thereof, are provided. Isolated and purified forms of the compounds are also described, as are unit dosage forms, compositions of substantially pure compound and kits comprising the compounds. The compounds and pharmaceutical compositions thereof may find use in the prevention and/or treatment of a variety of conditions, including prostate cancer, Parkinson's disease, Alzheimer's disease, and others.